Use of tryptophan metabolites for treating muscle atrophy
US11369595B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 5, 2017 |
| Grant date | Jun 28, 2022 |
| Priority date | — |
| Expiry date | Sep 5, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P21/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns a tryptophan metabolite chosen from kynurenic acid, anthranilic acid, quinolinic acid, picolinic acid, quinaldic acid and the mixtures of same or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt of same, for use as a drug intended for increasing and/or maintaining muscle mass and/or strength in a mammal, and in particular intended for treating and/or preventing muscle atrophy in mammals and/or for promoting muscle growth in mammals doing exercise and aiming to increase muscle mass and/or quality and/or strength, for preventing the appearance of symptoms of sarcopenia or for rehabilitation following muscle loss and/or for improving recovery time after an intense physical effort.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.